Actinium Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Actinium Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Actinium Pharmaceuticals Inc Strategy Report
- Understand Actinium Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Actinium Pharmaceuticals Inc (Actinium) develops antibody radiation conjugates (ARC), which combine antibodies' targeting ability with radiation's cell-killing ability. The company's pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for treating GeneTx and Cell therapy conditioning and Actimab-A(CD33) for treating relapsed/refractory AML. Its three variants of Actimab-A developed by the company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. ATNM is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
100 Park Ave., 23rd Floor, New York, 10017
Website
www.actiniumpharma.com
Telephone
1 646 6773870
No of Employees
49
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATNM (AFM)
Revenue (2022)
$81,000
-92.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-47.9%
(2022 vs 2021)
Market Cap*
$207.5M
Net Profit Margin (2022)
XYZ
-1,780.2%
(2022 vs 2021)
* As of and is in US$
Actinium Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Iomab-B |
| Actimab-A (CD33) and CLAG-M |
| Actimab-A (CD33) and Venetoclax |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In February, the company entered into a research and development agreement with the National Cancer Institute to develop Actimab-A for the treatment of patients with acute myeloid leukemia and other hematologic malignancies. |
| 2022 | Contracts/Agreements | In December, the company entered into a research collaboration with Columbia University to study Actimab-A with engineered hematopoietic stem cells modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. |
| 2022 | Contracts/Agreements | In March, the company and AVEO Oncology signed an agreement to develop and study a first-in-class antibody radio-conjugate targeting ErbB3, which is also known as HER3. |
Competitor Comparison
| Key Parameters | Actinium Pharmaceuticals Inc | Novartis AG | Telix Pharmaceuticals Ltd | POINT Biopharma Global Inc | Y-mAbs Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Australia | United States of America | United States of America |
| City | New York | Basel | Melbourne | Indianapolis | New York |
| State/Province | New York | - | Victoria | Indiana | New York |
| No. of Employees | 49 | 76,057 | 234 | 129 | 100 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sandesh Seth | Chief Executive Officer; Chairman | Executive Board | 2017 | 58 |
| Steve O’Loughlin | Chief Financial Officer | Senior Management | 2020 | 38 |
| Jenny Hsieh | Chief Strategy Officer | Senior Management | - | - |
| Avinash Desai, M.D. | Chief Medical Officer | Senior Management | - | - |
| Lynn Bodarky | Chief Business Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer